Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ORCL +8% (also forms form multi-cloud partnership with Google Cloud; also OpenAI selects Oracle to extend Microsoft Azure AI platform), CASY +4.7% (also increases dividend), RBRK +3.1%, ESI +1.3%
Other news:
- RTO +12.2% (Trian Fund amasses significant stake, according to Bloomberg)
- MREO +6.5% (Ultragenyx and Mereo BioPharma (MREO) Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta)
- DNTH +5.2% (FDA clearance of its Phase 2 Investigational New Drug application for the MoMeNtum trial of DNTH103 in patients with Multifocal Motor Neuropathy)
- IOVA +5.1% (disclosed stockholders' vote on five proposals)
- RARE +4.2% (Ultragenyx and Mereo BioPharma (MREO) Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta)
- PRLD +4.2% (provides investor updates and milestone timeline in presentation)
- RNA +3.6% (Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy)
- ARAY +3.4% (approval of the Accuray Precision treatment planning system by China's National Medical Products Administration)
- MAMO +3.1% (MAMO and BTOC announce strategic partnership)
- SCLX +3% (announces 5-year term of $100 million financing with royalty-based payments and potential strategic transactions with Perigrove and its portfolio companies)
- SUZ +2.2% (acquires a 15% stake in Lenzing AG from B&C Group)
- DNLI +2.1% (FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies)
- SMFG +1.8% (responds to ISS Report)
- AB +1.6% (reports May AUM)
- VCTR +1.5% (reports May AUM)
- SAVE +1.2% (negotiations with bondholders are progressing as expected; co also delays Analyst Day)
Analyst comments:
- KVYO +3.9% (upgraded to Overweight from Equal Weight at Barclays)
- NGG +3.5% (upgraded to Buy from Neutral at Goldman)
- CIEN +2.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- HAE +2% (upgraded to Buy from Hold at Needham)
- DAR +1.7% (upgraded to Buy from Neutral at Citigroup)
- MKC +1.1% (upgraded to Neutral from Sell at Citigroup)